Quoin Pharmaceuticals, Ltd. (QNRX) Form 8-K — Aug 28, 2026
$QNRXForm 8-KItems 1.01, 3.02, 7.01, 8.01, 9.01Filed Aug 28, 2026, 10:31 AM ET0001104659-26-102917Original filing
Quoin Pharmaceuticals priced a private placement on August 27, 2026 for gross proceeds of up to approximately $50.0 million, including $30.8 million at the August 31 closing and up to $19.2 million from cash exercises of Ordinary Warrants. The deal sells 6,305,300 ADSs (or pre-funded warrants) with warrants for up to 3,152,650 additional ADSs at a combined $4.88 per unit — the Nasdaq Minimum Price plus $0.0625 — for expected net proceeds of about $29.0 million.
Key figures
- Gross Proceeds
- up to approximately $50.0 million ($30.8 million upfront; up to $19.2 million from potential cash exercise of Ordinary Warrants)
- Offering Price
- $4.88 per ADS plus Ordinary Warrant ($4.8799 per Pre-Funded Warrant plus warrant)
- Shares Offered
- 6,305,300 ADSs (or Pre-Funded Warrants) plus Ordinary Warrants for up to 3,152,650 ADSs
- Cash Runway
- funded into the second half of 2029
- Debt Settled
- approximately $1,146,000
- Exchange Ads Issued
- 222574
- Prespecified Alpha
- 0.0215
- Topline Data Timing
- Q2 2027
- Net Proceeds Expected
- approximately $29.0 million
- Placement Fee Percent
- 6
- Iasi Improvement Range
- 31-87%
- Insider Participation
- 57,370 ADSs for approximately $280,000
- Primary Endpoint PValue
- 0.0087
- Study Enrollment Target
- approximately 20 participants
- Ads To Ordinary Share Ratio
- 1 ADS = 35 ordinary shares
- Secondary Endpoint PValue
- 0.007
- Primary Endpoint Response Rate
- 66.67% (4 of 6 participants)
- Ordinary Warrant Exercise Price
- $6.10 per ADS
- Pre Funded Warrant Exercise Price
- $0.0001
- Premium Over Nasdaq Minimum Price
- $0.0625
Price after filing
1 day: 0.0%7 days: +18.6%30 days: +5.1%
Close on the filing date to close N calendar days later (from $6.12). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.